62 / 76
HIPERTENSIÓN / 2017 / VOL. 22
62
Referencias
1. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database of Systematic Reviews.
2012(8).
2. Vidt DG. Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial. Cleve Clin J Med. 2000;67(6):429-33.
3. Rossitto G, Kamath G, Messerli FH. Q: Should alpha-blockers ever be used as antihypertensive drugs? Cleve Clin J Med. 2010;77(12):884-8.
4. Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich). 2005;7(12):757-62.
5. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539-53.
6. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors
of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA.
1998;280(13):1168-72.
7. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the
optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68.
8. Messerli FH, Grossman E. Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering
Treatment to Prevent Heart Attack Trial. Curr Hypertens Rep. 2000;2(3):241-2.
9. Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol. 2001;38(5):1295-6.
10. Chapman N, Chen CY, Fujita T, Hobbs FD, Kim SJ, Staessen JA, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management
of hypertension? J Hypertens. 2010;28(9):1796-803.
11. Pio-Abreu A, Drager LF. Resistant Hypertension: Time to Consider the Best Fifth Anti-Hypertensive Treatment. Curr Hypertens Rep. 2018;20(8):67.
12. Taraphder A. Alpha Adrenergic Blockers in the Treatment of Hypertension--A Nephrologist's Perspective. J Assoc Physicians India. 2014;62(9 Suppl):30-3.
13. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to
prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75.
14. Grimm RH, Jr., Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension.
Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA. 1996;275(20):1549-56.
15. Bryson CL, Psaty BM. A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy. Current Controlled Trials in
Cardiovascular Medicine. 2002;3(1):7-.
16. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-Drug Therapy for Hypertension in Men -- A Comparison of Six
Antihypertensive Agents with Placebo. New England Journal of Medicine. 1993;328(13):914-21.
17. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of Single-Drug Therapy on Reduction of Left Ventricular Mass in
Mild to Moderate Hypertension. Comparison of Six Antihypertensive Agents. 1997;95(8):2007-14.
18. Haridas A, Syrimi M, Al-Ahmar B, Hingorani M. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based
comparison of incidence and complication rates. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1541-5.